在临床试验中基于模拟的最低要求样本大小和功率,具有时间到事件终点和可变危险
Mohamed Mubasher1, Liang Shan2, Fengxia Yan1
1Community Health and Preventive Medicine Department Morehouse School of Medicine, Atlanta GA.
概括
这项研究通过模拟具有不同危险率的时间到事件数据来确定临床试验的最佳样本大小和功率. 结果指导有效的试验设计,用于准确的事件率分析.
科学领域:
- 临床试验 临床试验
- 生物统计学 生物统计学
- 生存分析的分析.
背景情况:
- 样本大小和统计能力对于临床试验设计具有时间到事件结果至关重要.
- 危险函数,描述事件发生率随时间的推移,是关键的,但可以变化 (恒定,下降,增加).
研究的目的:
- 确定临床试验的最低样本大小和功率要求.
- 调查不同危险功能模式对这些参数的影响.
- 为强有力的临床试验规划提供指导.
主要方法:
- 使用韦布尔分布模拟了两个独立的时间到事件数据样本.
- 多种危险模式 (恒定,下降,增加),尺度参数和后续持续时间.
- 分析模拟数据以评估样本大小和电力需求.
主要成果:
- 确定了在不同的韦布尔危险场景中有效的特定样本大小和功率组合.
- 证明了危险函数特征对所需统计功率的影响.
- 量化了不同尺度参数和随访期对试验设计的影响.
结论:
- 韦布尔分布在时间到事件分析中有效地模拟了可变危险函数.
- 基于模拟的方法对于优化临床试验样本大小和功率非常有价值.
- 准确地描述危险模式对于有效的临床试验设计至关重要.
相关概念视频
Assumptions of Survival Analysis
81
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
81
Comparing the Survival Analysis of Two or More Groups
113
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
113
Hazard Ratio
73
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
73
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
110
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
110
Introduction To Survival Analysis
150
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
150
Kaplan-Meier Approach
74
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
74


